Fibroblast News and Research RSS Feed - Fibroblast News and Research

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling. [More]
Study identifies BLU-554 as potential treatment option for HCC patients

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. [More]
FGF21 protein can boost regenerative effects of human PPARα

FGF21 protein can boost regenerative effects of human PPARα

Researchers at UC Davis have illuminated an important distinction between mice and humans: how human livers heal. The difference centers on a protein called PPARα, which activates liver regeneration. Normally, mouse PPARα is far more active and efficient than the human form, allowing mice to quickly regenerate damaged livers. [More]
Early response plus genetic variants strengthen antidepressant outcome prediction

Early response plus genetic variants strengthen antidepressant outcome prediction

Considering genetic variants in combination with early partial improvement could be useful for predicting antidepressant outcome, say researchers. [More]
Researchers develop new AFM system for imaging structural dynamics of living cells, neurons

Researchers develop new AFM system for imaging structural dynamics of living cells, neurons

While progress has been made over the past decades in the pursuit to optimize atomic force microscopy (AFM) for imaging living cells, there were still a number of limitations and technological issues that needed to be addressed before fundamental questions in cell biology could be address in living cells. [More]
Fat cell transplantation benefits systemic sclerosis patients with non-healing digital ulcers

Fat cell transplantation benefits systemic sclerosis patients with non-healing digital ulcers

Digital ulcers (DUs) are a frequent, painful, and quality of life altering complication for patients with systemic sclerosis (SSc), a connective tissue disease causing a progressive loss of small blood vessels and resulting changes in organs and tissues. DUs on the fingertips of SSc patients are slow to heal, if they heal at all, as many are unresponsive to any therapies. [More]
RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Researchers identify molecular pathways associated with distinct subsets of SSc patients

Researchers identify molecular pathways associated with distinct subsets of SSc patients

For years, doctors have been baffled about why some patients with systemic sclerosis (SSc) respond to therapy while others do not. [More]
Scientists identify new cellular pathway affected in cystinosis

Scientists identify new cellular pathway affected in cystinosis

Scientists at The Scripps Research Institute have identified a new cellular pathway that is affected in cystinosis, a rare genetic disorder that can result in eye and kidney damage. [More]
Researchers develop tri-layered artificial blood vessels

Researchers develop tri-layered artificial blood vessels

By combining micro-imprinting and electro-spinning techniques, researchers at Shanghai University's Rapid Manufacturing Engineering Center have developed a vascular graft composed of three layers for the first time. [More]
Study provides common model of cellular ageing

Study provides common model of cellular ageing

Researchers at the BBSRC-supported Babraham Institute have mapped the physical structure of the nuclear landscape in unprecedented detail to understand changes in genomic interactions occurring in cell senescence and ageing. Their findings have allowed them to reconcile the contradictory observations of two current models of ageing: cellular senescence of connective tissue cells called fibroblasts and cellular models of an accelerated ageing syndrome. [More]
Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children? [More]
U-M researchers devise reliable way to grow tumor cells

U-M researchers devise reliable way to grow tumor cells

In a development that could lead to a deeper understanding of cancer and better early-stage treatment of the disease, University of Michigan researchers have devised a reliable way to grow a certain type of cancer cells from patients outside the body for study. [More]
Growth hormone worthwhile treatment in hypochondroplasia

Growth hormone worthwhile treatment in hypochondroplasia

Researchers report that recombinant human growth hormone can improve growth in children with hypochondroplasia. [More]
Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other. [More]
Research shows FGF21 hormone acts directly on brain to regulate obesity

Research shows FGF21 hormone acts directly on brain to regulate obesity

A hormone seen as a popular target to develop weight-loss drugs works by directly targeting the brain and triggering previously unknown activity in the nervous system, UT Southwestern Medical Center obesity researchers have found. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health. [More]
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]
Advertisement
Advertisement